阿玛塔制药公司（NYSEAMERICAN：ARMP）空头兴趣显著增加

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Rating) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 34,900 shares, an increase of 52.4% from the February 28th total of 22,900 shares. Based on an average daily volume of 21,800 shares, the short-interest ratio is presently 1.6 days. Currently, 0.3% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Friday, March 17th.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN ARMP traded up $0.12 on Wednesday, reaching $1.67. 1,903 shares of the company's stock traded hands, compared to its average volume of 18,865. Armata Pharmaceuticals has a fifty-two week low of $0.83 and a fifty-two week high of $5.79. The company has a market capitalization of $60.37 million, a PE ratio of -1.53 and a beta of 1.27.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Rating) last announced its quarterly earnings data on Thursday, March 16th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The business had revenue of $1.05 million for the quarter, compared to analysts' expectations of $1.34 million. Armata Pharmaceuticals had a negative net margin of 670.26% and a negative return on equity of 75.16%. Research analysts expect that Armata Pharmaceuticals will post -1.31 earnings per share for the current year.

Institutional Investors Weigh In On Armata Pharmaceuticals

Large investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth $25,000. HRT Financial LP acquired a new position in shares of Armata Pharmaceuticals in the fourth quarter valued at approximately $52,000. Renaissance Technologies LLC raised its position in shares of Armata Pharmaceuticals by 5.6% in the fourth quarter. Renaissance Technologies LLC now owns 73,696 shares of the company's stock valued at $91,000 after buying an additional 3,900 shares during the last quarter. Northern Trust Corp acquired a new position in Armata Pharmaceuticals during the first quarter worth approximately $95,000. Finally, Vanguard Group Inc. increased its position in Armata Pharmaceuticals by 5.2% during the third quarter. Vanguard Group Inc. now owns 287,350 shares of the company's stock worth $1,213,000 after purchasing an additional 14,200 shares during the last quarter. 3.76% of the stock is owned by hedge funds and other institutional investors.

About Armata Pharmaceuticals

(Get Rating)

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Featured Stories

• Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
• Dave & Buster's Rebound Could Score for Investors
• Cal-Maine: Is it Time to Chase this Stock Higher?
• The Most Important Warren Buffett Stock for Investors: His Own
• Three Mid Caps Wall Street Sees Doubling Within 12 Months
• It's No Stretch: Lululemon Could Break Out of its Range

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.